Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
436 stopped studies mapped to Squamous Cell Carcinoma and descendants · 91% state a reason
Over the 436 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00784329 | Pilot Study To Evaluate Optical Frequency Domain Imaging For Diagnosis Of Central Airway… | N/A | withdrawn | Nov 3, 2008 | Lahey Clinic | not stated | Not stated |
| NCT03179956 | Impact of Ribociclib on Head and Neck Squamous Cell Cancer | Early Phase 1 | terminated | Jun 7, 2017 | Fox Chase Cancer Center | Slow accrual | Enrollment / accrual |
| NCT03346304 | Photodynamic Therapy for the Prevention of Lung Cancer(PEARL) | Phase 2 / Phase 3 | withdrawn | Nov 17, 2017 | University College, London | drug no longer available | Other (stated, no rule matched) |
| NCT02388932 | Stereotactic Body Radiation Therapy in Treating Patients With High Risk Locally Advanced… | N/A | terminated | Mar 17, 2015 | Case Comprehensive Cancer Center | Slow Accrual | Enrollment / accrual |
| NCT02205398 | Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and… | Phase 1 | terminated | Jul 31, 2014 | Novartis Pharmaceuticals | not stated | Not stated |
| NCT03246685 | Phase 2 Study of Imprime PGG & Pembrolizumab in Subjects With Adv SCCHN Who Failed Pembro… | Phase 2 | terminated | Aug 11, 2017 | HiberCell, Inc. | Due to enrollment challenges resulting in changing treatment patterns, the study has been… | Enrollment / accrual |
| NCT01764607 | Sirolimus in Kidney Transplant Patients With Squamous Cell Skin Carcinoma | Phase 2 | terminated | Jan 9, 2013 | University of Florida | Poor accrual | Enrollment / accrual |
| NCT03223662 | Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment… | Phase 2 | terminated | Jul 21, 2017 | National Cancer Institute (NCI) | Principal Investigator left the NIH. | Investigator |
| NCT02750033 | Intraoperative Margin Assessment During Mohs Surgery | — | withdrawn | Apr 25, 2016 | Seton Healthcare Family | Protocol changed to meet IRB requirements for patient safety | Safety / toxicity |
| NCT01732640 | A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative… | Phase 1 / Phase 2 | terminated | Nov 26, 2012 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Slow accrual and high levels of toxicity lead to early termination. | Safety / toxicity |
| NCT01852292 | Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus… | Phase 2 | terminated | May 13, 2013 | Novartis Pharmaceuticals | not stated | Not stated |
| NCT00488384 | Acitretin Plasma Levels Under Hemodialysis | Phase 4 | withdrawn | Jun 20, 2007 | Günther Hofbauer | lack of subjects | Other (stated, no rule matched) |
| NCT01164566 | Esophagoscopy in Evaluating Treatment in Patients With Stage I-IV Head and Neck Cancer… | N/A | terminated | Jul 16, 2010 | Wake Forest University Health Sciences | Inadequate Recruitment | Enrollment / accrual |
| NCT02552550 | Swallowing, Speech and Quality of Life of Patients With Carcinoma of the Oropharynx | — | terminated | Sep 17, 2015 | Centre Hospitalier Universitaire de Saint Etienne | rate of inclusion too low | Other (stated, no rule matched) |
| NCT00901537 | Azacitidine and Cisplatin in Patients With Advanced Lung or Head and Neck Cancer | Phase 1 | terminated | May 14, 2009 | Loma Linda University | Sponsor terminated due to no enrollments within last 4 months. | Enrollment / accrual |
| NCT01823679 | Capecitabine in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of… | Phase 2 | terminated | Apr 4, 2013 | Stanford University | Low accrual | Enrollment / accrual |
| NCT02365662 | A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced… | Phase 1 | terminated | Feb 19, 2015 | AbbVie | Safety | Safety / toxicity |
| NCT01627379 | Cisplatin and 5-FU +/- Panitumumab for Patients With Nonresectable,Advanced or Metastatic…(POWER) | Phase 3 | terminated | Jun 25, 2012 | AIO-Studien-gGmbH | Sponsor decision due to recommendation of the IDMC. | Sponsor / business decision |
| NCT01456143 | Optical Imaging of Head and Neck Cancer | N/A | terminated | Oct 20, 2011 | Sharmila Anandasabapathy, MD | PI left, study to be re-open with new PI, no planned data analysis | Investigator |
| NCT02407561 | Prospective Validation Study for the Proprietary Rectal and Anal Cancer Protein… | — | terminated | Apr 3, 2015 | Castle Biosciences Incorporated | Futility - unable to secure sites and samples for participation | Efficacy / futility |
| NCT01984892 | Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC)(Hiltonol) | Phase 2 | terminated | Nov 15, 2013 | Nina Bhardwaj | PI discretion, low enrollment | Enrollment / accrual |
| NCT01488318 | Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma | Phase 2 | terminated | Dec 8, 2011 | Julie E. Bauman, MD, MPH | PI leaving the institution | Other (stated, no rule matched) |
| NCT02993991 | Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous…(PRIMED-001) | Phase 1 | withdrawn | Dec 15, 2016 | University Health Network, Toronto | The study has been terminated due to a change in internal prioritization and not due to any safety… | Safety / toxicity |
| NCT01051791 | Phase II Study of RAD001 Head and Neck Cancer | Phase 2 | terminated | Jan 20, 2010 | Julie E. Bauman, MD, MPH | not stated | Not stated |
| NCT03307941 | Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced…(ARTEMIS-Eso) | Phase 1 / Phase 2 | withdrawn | Oct 12, 2017 | Jules Bordet Institute | Suspended collaboration with the company providing the study drug | Sponsor / business decision |
| NCT01221753 | Docetaxel/Cisplatin/5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell… | Phase 2 | terminated | Oct 15, 2010 | Dana-Farber Cancer Institute | Due to slow accrual | Enrollment / accrual |
| NCT00570674 | Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous… | Phase 1 / Phase 2 | terminated | Dec 11, 2007 | Dana-Farber Cancer Institute | The study did not continue to phase II due to the importance of HPV status as a prognostic factor… | Other (stated, no rule matched) |
| NCT02298595 | Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell Carcinoma | Phase 1 / Phase 2 | withdrawn | Nov 24, 2014 | Julie E. Bauman, MD, MPH | not stated | Not stated |
| NCT00070317 | Lymph Node Mapping and Sentinel Lymph Node Identification in Patients With Stage IB1… | N/A | terminated | Oct 7, 2003 | Gynecologic Oncology Group | not stated | Not stated |
| NCT00400205 | Study of Induction Docetaxel, Cisplatin and 5-Fluorouracil | Phase 2 | terminated | Nov 16, 2006 | Emory University | Safety reasons | Safety / toxicity |
| NCT02076243 | Treatment With Nab-paclitaxel in Cutaneous SCC | Phase 2 | terminated | Mar 3, 2014 | Icahn School of Medicine at Mount Sinai | Closed by sponsor | Other (stated, no rule matched) |
| NCT02068157 | Interstitial Photodynamic Therapy in Treating Patients With Recurrent Head and Neck Cancer | Phase 2 | terminated | Feb 21, 2014 | Roswell Park Cancer Institute | Study no longer has an active IDE | Other (stated, no rule matched) |
| NCT02211027 | Biological Vaccine: Semi-allogeneic Human Fibroblasts (MRC-5) Transfected With DNA | Phase 1 | withdrawn | Aug 7, 2014 | Robert Ferris | not stated | Not stated |
| NCT02538627 | Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib | Phase 1 | terminated | Sep 2, 2015 | Merrimack Pharmaceuticals | Sponsor decision | Sponsor / business decision |
| NCT01740375 | Role of Esophagectomy in Complete Responders to CCRT(ESOPRESSO) | Phase 3 | terminated | Dec 4, 2012 | Asan Medical Center | slow recruitment | Enrollment / accrual |
| NCT02223975 | Evaluation of the Role of Vibrational Spectroscopy in the Assessment of Vulval Disease(Vulval VS) | — | suspended | Aug 22, 2014 | Gloucestershire Hospitals NHS Foundation Trust | Study suspended pending further funding | Funding |
| NCT02321982 | Same-day Versus Separate-day Preoperative Consultation for Mohs Surgery | N/A | withdrawn | Dec 22, 2014 | Dartmouth-Hitchcock Medical Center | Study topic is no longer being pursued by study team members | Other (stated, no rule matched) |
| NCT01148082 | School Response to Families Who Have Children With Cancer | — | withdrawn | Jun 22, 2010 | Stanford University | Business decision | Sponsor / business decision |
| NCT00591149 | Oxaliplatin and Docetaxel Followed by Cetuximab for Head and Neck Cancer | Phase 2 | terminated | Jan 11, 2008 | University of Kansas Medical Center | Study was stopped due to termination of funding | Funding |
| NCT01303237 | A Post Marketing Surveillance Study to Assess the Safety and Efficacy of Cetuximab Plus…(PMS LAD SCCHN) | — | terminated | Feb 24, 2011 | Merck KGaA, Darmstadt, Germany | The study was discontinued due to slow recruitment and subjects not completing follow up period. | Enrollment / accrual |
| NCT02593929 | Pharmacodynamic Effects and Predictive Biomarkers With Ruxolitinib in Operable Head and… | Early Phase 1 | withdrawn | Nov 2, 2015 | University of Pittsburgh | not stated | Not stated |
| NCT00632203 | Study of Maintenance Temozolomide Versus Observation in Stable or Responding Stage III/IV… | Phase 2 | terminated | Mar 10, 2008 | Merck Sharp & Dohme LLC | not stated | Not stated |
| NCT00895245 | Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing… | Phase 2 | terminated | May 8, 2009 | University of Washington | Study stopped due to lack of efficacy in first 6 patients | Efficacy / futility |
| NCT01794845 | Cetuximab + Taxotere With Low Dose Fractionated Radiation for Head and Neck Carcinoma | Phase 2 | terminated | Feb 20, 2013 | University of Miami | Early termination due to lack of efficacy (overall response) | Efficacy / futility |
| NCT01142869 | An Observational Study to Evaluate the Safety and Efficacy of Cetuximab in Combination… | — | terminated | Jun 11, 2010 | Merck KGaA, Darmstadt, Germany | The study was discontinued due to slow recruitment and subjects not completing follow up period. | Enrollment / accrual |
| NCT02045186 | Monitoring of Oral Human Papillomavirus Infection (HPV) in HPV-positive Oropharyngeal… | N/A | terminated | Jan 24, 2014 | UNC Lineberger Comprehensive Cancer Center | not stated | Not stated |
| NCT02196168 | Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or… | Phase 2 | terminated | Jul 21, 2014 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT02567396 | Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be… | Phase 1 | withdrawn | Oct 5, 2015 | National Cancer Institute (NCI) | Other- Protocol moved to Disapproved | Other (stated, no rule matched) |
| NCT01267240 | Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head… | Phase 2 | terminated | Dec 28, 2010 | National Cancer Institute (NCI) | Study treatment did not show clinical activity. | Other (stated, no rule matched) |
| NCT00392665 | Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck | Phase 2 | terminated | Oct 26, 2006 | Massachusetts General Hospital | slow accrual | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Mar 12, 2019source: clinicaltrials